Lumos Change In Cash from 2010 to 2024

LUMO Stock  USD 2.25  0.04  1.75%   
Lumos Pharma Change In Cash yearly trend continues to be very stable with very little volatility. Change In Cash is likely to grow to about -19.9 M this year. During the period from 2010 to 2024, Lumos Pharma Change In Cash quarterly data regression pattern had sample variance of 2668 T and median of (3,870,000). View All Fundamentals
 
Change In Cash  
First Reported
2009-12-31
Previous Quarter
-479 K
Current Value
-11.9 M
Quarterly Volatility
25.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lumos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lumos main balance sheet or income statement drivers, such as Depreciation And Amortization of 41.8 K, Interest Expense of 671.3 K or Selling General Administrative of 18.6 M, as well as many exotic indicators such as Price To Sales Ratio of 12.0, Dividend Yield of 0.0 or PTB Ratio of 1.0. Lumos financial statements analysis is a perfect complement when working with Lumos Pharma Valuation or Volatility modules.
  
This module can also supplement various Lumos Pharma Technical models . Check out the analysis of Lumos Pharma Correlation against competitors.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

Latest Lumos Pharma's Change In Cash Growth Pattern

Below is the plot of the Change In Cash of Lumos Pharma over the last few years. It is Lumos Pharma's Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lumos Pharma's overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Pretty Stable
   Change In Cash   
       Timeline  

Lumos Change In Cash Regression Statistics

Arithmetic Mean6,409,230
Geometric Mean25,226,794
Coefficient Of Variation805.91
Mean Deviation38,396,113
Median(3,870,000)
Standard Deviation51,652,859
Sample Variance2668T
Range193.2M
R-Value(0.28)
Mean Square Error2646.8T
R-Squared0.08
Significance0.31
Slope(3,242,671)
Total Sum of Squares37352.2T

Lumos Change In Cash History

2024-19.9 M
2023-20.9 M
2022-38.8 M
2021-3.9 M
202093.7 M
2019-30.2 M
2018-38 M

About Lumos Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Lumos Pharma income statement, its balance sheet, and the statement of cash flows. Lumos Pharma investors use historical funamental indicators, such as Lumos Pharma's Change In Cash, to determine how well the company is positioned to perform in the future. Although Lumos Pharma investors may use each financial statement separately, they are all related. The changes in Lumos Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lumos Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Lumos Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Lumos Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change In Cash-20.9 M-19.9 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:
Check out the analysis of Lumos Pharma Correlation against competitors.
To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Lumos Stock analysis

When running Lumos Pharma's price analysis, check to measure Lumos Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lumos Pharma is operating at the current time. Most of Lumos Pharma's value examination focuses on studying past and present price action to predict the probability of Lumos Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lumos Pharma's price. Additionally, you may evaluate how the addition of Lumos Pharma to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stocks Directory
Find actively traded stocks across global markets
Is Lumos Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.58)
Revenue Per Share
0.252
Quarterly Revenue Growth
0.613
Return On Assets
(0.41)
Return On Equity
(0.78)
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.